BofA lowered the firm’s price target on Acumen (ABOS) to $9 from $10 and keeps a Buy rating on the shares, citing the updated cash position following a Q2 report the firm calls “(understandably) quiet.” The “key update” was the phase 2 ALTITUDE-AD of sabirnetug in early AD remains on track to read-out late 2026, the analyst added.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS: